HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients.

AbstractBACKGROUND:
Levosimendan has been extensively used to treat heart failure (HF) for nearly 10 years, but data on levosimendan used in elderly patients with refractory HF remains limited. This study aimed to investigate the effects of levosimendan on elderly patients with intractable HF.
MATERIAL AND METHODS:
A total of 268 patients with HF (over 70 years, New York Heart Association [NYHA] classification III-IV, LVEF ≤40%, plasma NT-proBNP ≥1000 pg/mL) received conventional anti-HF therapies for 2 weeks. Such therapies include the limiting of salt intake, increasing myocardial contractility (without levosimendan), inducing urine, antagonizing aldosterone, antagonizing myocardial remodeling, and, if necessary, using antibiotics. Our study included 42 patients without symptoms whose improvement was re-evaluated and presented in NYHA class III-IV, LVEF ≤40%, plasma NT-proBNP ≥1000.0 pg/mL, and serum creatinine <110.0 µmol/L. These patients were divided into an experimental groups (n=21, treated with levosimendan) and a control group (n=21, continuously given regular treatment as before). After 1 week, 42 patients were assessed for changes in NYHA classification, LVEF, and NT-proBNP.
RESULTS:
No severe complications related to levosimendan were noted. Compared with the control group, NYHA classification (I-II: 1 versus 21, III-IV: 20 versus 0, P<0.05) and LVEF (30.62±6.19% versus 45.83±5.06%, P<0.05) were increased, and plasma NT-proBNP was reduced (458.35±193.16 pg/mL versus 2921.52±1395.97 pg/mL, P<0.05) in the experimental group.
CONCLUSIONS:
Our study showed levosimendan significantly and safely improved clinical outcomes of refractory heart failure in elderly patients.
AuthorsDengqing Zhang, Yuanqing Yao, Jun Qian, Jing Huang
JournalMedical science monitor : international medical journal of experimental and clinical research (Med Sci Monit) Vol. 21 Pg. 2439-45 (Aug 20 2015) ISSN: 1643-3750 [Electronic] United States
PMID26289557 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Arrhythmia Agents
  • Hydrazones
  • Peptide Fragments
  • Pyridazines
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Simendan
  • Creatinine
Topics
  • Aged
  • Aged, 80 and over
  • Anti-Arrhythmia Agents (therapeutic use)
  • Asian People
  • China
  • Creatinine (blood)
  • Female
  • Heart Failure (blood, drug therapy, physiopathology)
  • Humans
  • Hydrazones (therapeutic use)
  • Male
  • Natriuretic Peptide, Brain (blood)
  • Peptide Fragments (blood)
  • Prospective Studies
  • Pyridazines (therapeutic use)
  • Simendan
  • Stroke Volume (drug effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: